1. FIELD OF INVENTION
A NOVEL BIOAVAILBLE TOTAL GYMNEMIC ACIDS FROM GYMNEMA SYLVESTRE LEAVES
DESCRIPTION OF THE INVENTION
Despite the use of oral anti -diabetic drugs, Diabetes Mellitus continues to be a worldwide disease. The number of patients suffering from diabetes is increasing widely. Many of the synthetic drugs available doesn't possess potential benefits. This has led to the emergence of pursuing of natural drugs. But in the case of many natural drugs the major problem is the lack of clinical evidences and many of them are not bio available also. G. sylvestre (Asclepiadaceae) a vulnerable species is a slow growing, perennial, medicinal woody climber found in central and peninsular India. The leaf extract of Gymnemic acid is found to possess potential anti diabetic property. Our present invention relates the isolation of a plant derived phytochemical with increased bio availability.

2. SUMMARY OF THE INVENTION
- The anti-diabetic array of molecules has been identified as a group of closely related gymnemic acids after it was successfully isolated and purified from the leaves of G. sylvestre. Gymnemic acids are group of triterpenoid saponins belonging to oleanane and dammarene classes. Oleanane saponins are gymnemic acids and gymnemasaponins, while dammarene saponins are gymnemasides. Gymnemic acids I-VI were isolated and characterized from leaf extracts and gymnemic acids XV-XVIII from the saponin fraction of the leaves. Gymnemic acids VlII-XII have been elucidated as glucosideuronic acid derivatives of gymnemagenin. Gymnemic acids are thought to be responsible for the antidiabetic activity of G. sylvestre; gymnemic acid VIII was the major component of an extract shown to stimulate insulin release from the pancreas. The atomic and molecular arrangement of gymnemic iacid is similar to that of glucose. These molecules fill the receptor locations on the taste buds thereby preventing its activation by sugar molecules present in the food, thereby curbing the sugar craving. Similarly, Gymnemic acid molecules fill the receptor location in the absorptive external layers of the intestine thereby preventing the sugar molecules absorption by the intestine, which results in low blood sugar level. It is shown to increase the activities of enzymes responsible for utilization of glucose by insulin-dependent pathways, an increase in phosphorylase activity, decrease in gluconeogenic enzymes and sorbitol dehydrogenase. It causes inhibition of glucose absorption from intestine, the exact action being unknown. Our novel extraction procedure and encapsulation technology in beta Cyclodextrin matrix allows ensures the efficiency of the drug.

3. BACKGROUND OF THE INVENTION
Gymnemic acids are the active compounds responsible for the anti diabetic property of the extract. Suitable extraction and encapsulation technology plays a major role in ensuring the efficiency of the drug. The structures of the active components are depicted below
The present invention relates the development of a novel product encapsulated in beta Cyclodextrin.
Ingredients used:
Gymnema Sylvestre leaf Extract Beta Cyclodextrin

I claim,
1. A novel bioavailable total gymnemic acids from gymnema sylvestre leaves
2. A product according to claim 1, a bio available product
3. A product according to claim 1, can be used as a anti diabetic product